SKYRIZI 75 mg, solution for injection in a pre-filled syringe 2 syringes of 0.83 ml
Active ingredients: Risankizumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection2 syringes of 0.83 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SKYRIZI 75 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 2 seringues préremplies en verre de 0,83 ml (75 mg/0,83 ml) + 2 compresses d’alcool
- Marketing authorisation holder
- ABBVIE DEUTSCHLAND (ALLEMAGNE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 27 Sept 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67060271CIP73017488CIP133400930174883Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RISANKIZUMABsolution | 75 mg · une seringue préremplie de 0,83 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.